IL2 and myocardial infarction: Bouchentouf et al 2011 showed that a single intravascular injection of recombinant human IL‐2(rhIL‐2) two days following myocardial infarction (MI) improved the left ventricular (LV) ejection fraction by 27.7% of immune competent mice but did not affect the cardiac function of the immunodeficient (NOD‐SCID IL2Rα null) mice.